5-(4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]benzyl)-5-(4-methylbenzenesulfonyl)thiazolidine-2,4-dione | 500718-69-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]benzyl)-5-(4-methylbenzenesulfonyl)thiazolidine-2,4-dione
• 英文别名: 5-[[4-[2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-5-(4-methylphenyl)sulfonyl-1,3-thiazolidine-2,4-dione
• CAS: 500718-69-4
• 化学式: C₂₉H₂₆N₂O₆S₂
• 分子量: 562.667
• InChiKey: DUUDQIKTDOHQTI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  39
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  149
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• 5-(Substituted)-5-(substitutedsulfonyl or sulfanyl) thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase
  申请人：American Cyanamid Company

  公开号：US20030096849A1

  公开（公告）日：2003-05-22

  The invention relates to compounds of Formula (I) wherein R 1 , (R 2 ) v , R 3 and n are defined in the specification and pharmaceutical compositions thereof, that inhibit the Ras farnesyl-protein transferase enzyme (FPTase), and may be used as an alternative to, or in conjunction with, traditional cancer therapy for the treatment of ras oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid. 1

  本发明涉及式（I）的化合物，其中R1，（R2）v，R3和n在规范中定义，并且其制药组合物抑制Ras法尼醇蛋白转移酶（FPTase），可用作替代或与传统癌症治疗相结合，用于治疗ras癌基因依赖性肿瘤，如胰腺癌，结肠癌，膀胱癌和甲状腺癌。
• US6716862B2
  申请人：——

  公开号：US6716862B2

  公开（公告）日：2004-04-06
• [EN] 5-(SUBSTITUTED)-5-(SUBSTITUTEDSULFONYL OR SULFANYL)THIAZOLIDINE-2,4-DIONES USEFUL FOR INHIBITION OF FARNESYL-PROTEIN TRANSFERASE<br/>[FR] 5-(SUBSTITUE)-5-(SUBSTITUE SULFONYL OU SULFANYL)THIAZOLIDINE-2,4-DIONES UTILES POUR L'INHIBITION DE LA FARNESYL-PROTEINE TRANSFERASE
  申请人：WYETH CORP

  公开号：WO2003018011A1

  公开（公告）日：2003-03-06

  The invention relates to compounds of Formula (I) wherein R1, (R2)v, R3 and n are defined in the specification, to processes for their preparation and pharmaceutical compositions thereof, that inhibit the Ras farnesyl-protein transferase enzyme (FPTase), and may be used as an alternative to, or in conjunction with, traditional cancer therapy for the treatment of ras oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid.